Good News for the Bubble Baby Disease Treatment Backed by Millions from California Taxpayers
By David Jensen,
The California Stem Cell Report
| 02. 15. 2022
Photo: CIRM
Twenty children seeking treatment for a rare affliction called the “bubble baby disease” today have some big-time, good news concerning a life-saving genetic therapy that they were once denied as the result of a tangled affair involving private profit and the public funding of cutting-edge scientific research.
After being halted nearly two years ago, a California state-financed clinical trial that can help the children is now solidly on its way to a new beginning at UCLA. Treatments of the children could begin as early as June.
The California stem cell agency is expected to provide $5.8 million to resume the trial at UCLA. Millions more are likely to be forthcoming from the agency, officially known as the California Institute for Regenerative Medicine (CIRM).
Despite the success of the trial over the last several years -- “100 percent overall survival” of 50 patients -- it was abandoned in 2020 by Orchard Therapeutics, PLC. Instead, Orchard turned towards research that it deemed would be more profitable. At that time, Orchard had exclusive rights to the therapy, which was...
Related Articles
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Judd Boaz and Elise Kinsella, ABC News | 03.17.2026
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...
